For example, supplementation with SCFAs for kidney and liver diseases, inflammatory bowel disease, and colon cancer reduced the pro-inflammatory mediators, tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and C-reactive protein, as well as disease progression [45]. This evidence concerns the gene IL6 and liver disorder.